LivaNova PLC
Performance History
| Key Stats | |
|---|---|
| Open | $44.97 |
| Prev. Close | $44.87 |
| EPS | 0.05 |
| Dividend | $0.00 |
| Next Earnings Date | Jul 26, 2023 |
| Dividend Yield % | - |
| Market Cap | $2.41B |
| PE Ratio | 897.00 |
| low | high | |
|---|---|---|
| Day Range | 44.71 | 45.87 |
| 52 Week Range | 40.26 | 59.86 |
| Ratios | |
|---|---|
| P/B Ratio | 1.97 |
| Revenue | $1.11B |
| Operating M. % | 1.56% |
| Earnings | $2.90M |
| Earnings Growth % | 13.26% |
| EBITDA Margin % | 10.11% |
| ROE % | 0.24% |
| EPS | 0.05 |
Score Breakdown
All Score (59 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| LIVN | Market | |
|---|---|---|
| Value | 41 | 42 |
| Quality | 52 | 46 |
| Ownership | 53 | 39 |
| Growth | 60 | 44 |
| Dividends | - | 32 |
All Score (59 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About LivaNova PLC (LIVN)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. It also engages in research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
- ISN
- -
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Mr. William A. Kozy
- Headquarters
- London
- Employees
- 2900
Keep an eye on LivaNova PLC
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.